0.1607
900 319 0030
x

Role of PSUs in Drug Accessibility

iasparliament Logo
March 14, 2018

What is the issue?

  • The WHO has invited expressions of interest to produce generic versions of an anti-tubercular drugs.
  • India need to use this opportunity to shore up public sector capacity for making medicines.

What is international convention for drug accessibility?

  • Compulsory licensing (CL) is a mechanism permitted by the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement.
  • This enable countries to issue licences to domestic drug manufacturers to produce and market affordable generic versions of life-saving drugs.
  • This allows countries to overcome patent restrictions to assure availability of such drugs when the situation demands.
  • Drugs effective against multi-drug resistant tuberculosis and anti-cancer drugs are clear examples of such a need, which should be addressed through compulsory licensing.

What is the significant role of India in pharma sector?

  • India is rightly acclaimed to be the pharmacy of the world, with its huge private sector capacity for producing branded and unbranded generic drugs.
  • India opted for process patenting over product patenting in 1970, this changed to a product patent regime in 2005.
  • This has provided a sufficient time for growth of the generic drug industry in the private sector.
  • India has used the CL route previously to permit two Indian companies, to produce a potent anti-cancer drug nexavar, this enabled a 32-fold reduction in the cost of the drug.

What are practical concerns with Indian drug industry?

  • Growth of Private sector - The growth of Private drug industry has led to the decline and near disappearance of public sector capacity for manufacture of drugs and vaccines.  
  • Similarly, drugs for neglected tropical diseases are of little interest to the commercially driven private drug industry.
  • Patent regulations - In India the experience of price negotiation with the patent-holding companies is not encouraging, if they do not see evidence of a government’s intent to use the CL route as an imminent possibility.
  • If the domestic private sector drug manufacturers are not ready to apply for CL, public sector capacity to seek and utilise such licences becomes indispensable.
  • Import of raw materials - Active pharmaceutical ingredients (APIs), which are needed for drug manufacture (formulation), are now mostly imported from China.
  • This makes India highly vulnerable to disruptions in supply and cost escalations in import.

What is the role of PSUs in universal drug accessibility?

  • Compulsory licences need to be issued by the government for patent protected drugs or even off-patent drugs which are commercially unattractive to private manufacturers.
  • The role of PSUs will offer an opportunity to produce drug volumes for use in primary and secondary care facilities as well as help in ‘benchmarking’ drug costs.
  • The existence of PSUs would also provide an opportunity to utilise the provision of Compulsory Licensing under TRIPS.
  • Effective implementation of the Ayushman Bharat initiative calls for investment in expanding public sector capacity for producing essential drugs.
  • National security demands with suitable government support and incentives, to ensure uninterrupted and inexpensive availability of APIs is need of the hour.
  • Thus active public sector capacity is needed to ensure that Indians are not denied access to essential drugs.

 

Source: The Hindu

 

Login or Register to Post Comments
There are no reviews yet. Be the first one to review.

ARCHIVES

MONTH/YEARWISE ARCHIVES

Free UPSC Interview Guidance Programme